Kodiak Sciences Announces First Patients Enrolled in Global Phase 3 ALTO trial of KSI-501 in Patients with Diabetic Macular Edema
Kodiak Sciences has enrolled the first patients in the global Phase 3 ALTO trial evaluating KSI-501 for diabetic macular edema. The study is designed to demonstrate the superiority of the bispecific therapy versus aflibercept and aims to enroll approximately 910 patients across three dosing arms.
Key figures
- Drug Name
- KSI-501
- Phase Of Trial
- Phase 3
- Patient count
- 910
- Primary endpoint weeks
- 48 and 52
- Market size opportunity
- $15 billion
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.